Pre-diagnostic short sleep duration, frequent snoring associated with poor cancer-specific survival

NewsGuard 100/100 Score

A new study suggests that pre-diagnostic short sleep duration and frequent snoring were associated with significantly poorer cancer-specific survival, particularly among women with breast cancer.

Results show that stratified by cancer site, short sleep duration and frequent snoring were associated with significantly poorer breast cancer-specific survival.

"Our results suggest that sleep duration is important for breast cancer survival, particularly in women who snore," said lead author Amanda Phipps, assistant professor of epidemiology at the University of Washington in Seattle, Wash. and assistant member at the Fred Hutchinson Cancer Research Center.

The research abstract was published recently in an online supplement of the journal Sleep and will be presented Wednesday, June 10, in Seattle, Washington, at SLEEP 2015, the 29th annual meeting of the Associated Professional Sleep Societies LLC.

The study group comprised of 21,230 women diagnosed with a first primary invasive cancer during follow-up from the Women's Health Initiative (WHI). Participants provided information on several sleep attributes at study baseline, including sleep duration, snoring, and components of the WHI Insomnia Rating Scale. Analyses were adjusted for age at enrollment, study arm, cancer site, marital status, household income, smoking, physical activity, and time-lag between baseline data collection and cancer diagnosis.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels